The History of Rare Bleeding Disorders

Abstract

Deficiencies in coagulation factors I (FI), FII, FV, combined FV and FVIII (CF5F8) and vitamin K-dependent coagulation factors FVII, FX, FXI, and FXIII have been referred to as rare bleeding disorders (RBDs), rare coagulation factor deficiencies (RCFDs), or recessively inherited coagulation disorders. Fibrinogen was most likely the first member of this group to be identified, with reports of its discovery spanning from 1859 to 1966. If not, then the first coagulation factor to be identified was prothrombin in 1894, and the last coagulation factor to be found was FX in 1956, about 60 years later. The first patient to be diagnosed with an RBD was a 9-year-old boy with afibrinogenemia in 1920 and the vitamin K-dependent coagulation factors deficiency was the most recent RBD in this group to be identified in a 3-month-old child in 1966. The initial therapeutic option for nearly all patients with RBDs was whole blood transfusion; this was replaced in 1941 by fresh frozen plasma (FFP), and then in later years by cryoprecipitate and coagulation factor concentrates. Fibrinogen concentrate was the first coagulation factor concentrate produced in 1956. Coagulation factor concentrate is now available for FI, FVII, FX, FXI, and FXIII; however, FFP and/or platelet transfusion are the only treatments available for FV deficiency. The only recombinant concentrates available for RBDs are for FVII and FXIII, which date from 1988 and the 2000s, respectively. Even though the clinical presentations, diagnosis, and management of lesser-known bleeding disorders have improved significantly in recent decades, more studies are needed to reveal the hidden aspects of these disorders in order to overcome diagnostic and therapeutic challenges and ultimately improve the quality of life for those who are affected.

Keywords

rare bleeding disorders - congenital fibrinogen disorders - prothrombin deficiency - factor V deficiency - factor VII deficiency

Publikationsverlauf

Artikel online veröffentlicht:
04. November 2024

• References

• 1 Dorgalaleh A, Bahraini M, Shams M. et al. Molecular basis of rare congenital bleeding disorders. Blood Rev 2023; 59: 101029
• 2 Dorgalaleh A, Tabibian S, Hosseini MS, Shams M. Pharmacological management of rare coagulation factor deficiencies besides hemophilia. Expert Rev Hematol 2020; 13 (08) 811-834
• 3 Shapiro A. The use of prophylaxis in the treatment of rare bleeding disorders. Thromb Res 2020; 196: 590-602
• 4 Rodríguez MF. Diagnosing rare bleeding disorders. Blood Coagul Fibrinolysis 2022; 33 (Suppl. 01) S15-S16
• 5 Kattula S, Byrnes JR, Wolberg AS. Fibrinogen and fibrin in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 2017; 37 (03) e13-e21
• 6 Surma S, Banach M. Fibrinogen and atherosclerotic cardiovascular diseases—review of the literature and clinical studies. Int J Mol Sci 2021; 23 (01) 193
• 7 Casini A, Moerloose P, Neerman-Arbez M. One hundred years of congenital fibrinogen disorders. Semin Thromb Hemost 2022; 48 (08) 880-888
• 8 Rabe F. Uber-faserstoffmangel in biute bei einem falle von haemophilie. Arch Med (Oviedo) 1920; 95: 2
• 9 Allibone EC, Baar HS. Fibrinogen deficiency as a factor in haemorrhagic disease. Arch Dis Child 1943; 18 (95) 146-153
• 10 Ramanan R, McFadyen JD, Perkins AC, Tran HA. Congenital fibrinogen disorders: strengthening genotype-phenotype correlations through novel genetic diagnostic tools. Br J Haematol 2023; 203 (03) 355-368
• 11 Blombäck M, Blombäck B, Mammen EF, Prasad AS. Fibrinogen Detroit – a molecular defect in the N-terminal disulphide knot of human fibrinogen?. Nature 1968; 218 (5137): 134-137
• 12 Neerman-Arbez M, Honsberger A, Antonarakis SE, Morris MA. Deletion of the fibrinogen alpha-chain gene (FGA) causes congenital afibrogenemia. J Clin Invest 1999; 103 (05) 759
• 13 Kerr CB. Genetics of human blood coagulation. J Med Genet 1965; 2 (04) 254-303
• 14 Pfeifer U, Ormanns W, Klinge O. Hepatocellular fibrinogen storage in familial hypofibrinogenemia. Virchows Arch B Cell Pathol Incl Mol Pathol 1981; 36 (2-3): 247-255
• 15 Brennan SO, Wyatt J, Medicina D, Callea F, George PM. Fibrinogen brescia: hepatic endoplasmic reticulum storage and hypofibrinogenemia because of a γ284 Gly–>Arg mutation. Am J Pathol 2000; 157 (01) 189-196
• 16 Council on Pharmacy and Chemistry. J Am Med Assoc 1941; 117 (11) 934-935
• 17 Pool JG, Gershgold EJ, Pappenhagen AR. High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate. Nature 1964; 203 (4942): 312
• 18 Nair PM, Rendo MJ, Reddoch-Cardenas KM, Burris JK, Meledeo MA, Cap AP. Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease. Semin Hematol 2020; 57 (02) 73-82
• 19 Nitschmann H, Kistler P, Joss A. Dried fraction I for clinical use from smallest plasma pools, sterile without filtration. Vox Sang 1957; 2 (02) 100-103
• 20 Costa-Filho R, Hochleitner G, Wendt M, Teruya A, Spahn DR. Over 50 years of fibrinogen concentrate. Clin Appl Thromb Hemost 2016; 22 (02) 109-114
• 21 Simurda T, Asselta R, Zolkova J. et al. Congenital afibrinogenemia and hypofibrinogenemia: laboratory and genetic testing in rare bleeding disorders with life-threatening clinical manifestations and challenging management. Diagnostics (Basel) 2021; 11 (11) 2140
• 22 Batsuli G, Kouides P. Rare coagulation factor deficiencies (factors VII, X, V, and II). Hematol Oncol Clin North Am 2021; 35 (06) 1181-1196
• 23 Strauss ER, Mazzeffi MA, Williams B, Key NS, Tanaka KA. Perioperative management of rare coagulation factor deficiency states in cardiac surgery. Br J Anaesth 2017; 119 (03) 354-368
• 24 Lancellotti S, De Cristofaro R. Congenital prothrombin deficiency. Semin Thromb Hemost 2009; 35 (04) 367-381
• 25 Schmidt A. Neue untersuchungen über die faserstoffgerinnung. Archiv für die gesamte Physiologie des Menschen und der Tiere 1872; 6 (01) 413-538
• 26 Hemker HC. Interplay between medicine and biochemistry. New Comprehensive Biochemistry. 13: Elsevier; 1986: 307-312
• 27 Quick AJ. Congenital hypoprothrombinaemia and pseudo-hypoprothrombinaemia. Lancet 1947; 2 (6472): 379-382
• 28 Quick AJ, Hussey CV. Hereditary hypoprothrombinaemias. Lancet 1962; 1 (7222): 173-177
• 29 Quick AJ, Pisciotta AV, Hussey CV. Congenital hypoprothrombinemic states. AMA Arch Intern Med 1955; 95 (01) 2-14
• 30 Girolami A, Scarano L, Saggiorato G, Girolami B, Bertomoro A, Marchiori A. Congenital deficiencies and abnormalities of prothrombin. Blood Coagul Fibrinolysis 1998; 9 (07) 557-569
• 31 Poort SR, Michiels JJ, Reitsma PH, Bertina RM. Homozygosity for a novel missense mutation in the prothrombin gene causing a severe bleeding disorder. Thromb Haemost 1994; 72 (06) 819-824
• 32 Girolami A, Coccheri S, Palareti G, Poggi M, Burul A, Cappellato G. Prothrombin Molise: a “new” congenital dysprothrombinemia, double heterozygosis with an abnormal prothrombin and “true” prothrombin deficiency. Blood 1978; 52 (01) 115-125
• 33 Tamary H, Surrey S, Augustine J, Shalmon L, Schwartz E, Rappaport EF. Molecular analysis of a compound heterozygote for hypoprothrombinemia and dysprothrombinemia (-G 7248/7249 and ARG 340 TRP). Blood Coagul Fibrinolysis 1997; 8 (06) 337-343
• 34 Strijks E, Poort SR, Renier WO, Gabreëls FJ, Bertina RM. Hereditary prothrombin deficiency presenting as intracranial haematoma in infancy. Neuropediatrics 1999; 30 (06) 320-324
• 35 Ferguson JH, Lewis JH, Fresh JW. The two-stage prothrombin assay in study of bleeding and clotting disorders. Yale J Biol Med 1955; 28 (3-4): 253-264
• 36 Menegatti M, Peyvandi F. Treatment of rare factor deficiencies other than hemophilia. Blood 2019; 133 (05) 415-424
• 37 Stormorken H. The discovery of factor V: a tricky clotting factor. J Thromb Haemost 2003; 1 (02) 206-213
• 38 Mann KG, Kalafatis M. Factor V: a combination of Dr Jekyll and Mr Hyde. Blood 2003; 101 (01) 20-30
• 39 Duga S, Asselta R, Tenchini ML. Coagulation factor V. Int J Biochem Cell Biol 2004; 36 (08) 1393-1399
• 40 Kane WH, Ichinose A, Hagen FS, Davie EW. Cloning of cDNAs coding for the heavy chain region and connecting region of human factor V, a blood coagulation factor with four types of internal repeats. Biochemistry 1987; 26 (20) 6508-6514
• 41 Cripe LD, Moore KD, Kane WH. Structure of the gene for human coagulation factor V. Biochemistry 1992; 31 (15) 3777-3785
• 42 Stoj KM, Pierro J. Factor V Deficiency. StatPearls. Treasure Island, FL: StatPearls Publishing Copyright © 2024, StatPearls Publishing LLC.; 2024
• 43 Murray JM, Rand MD, Egan JO, Murphy S, Kim HC, Mann KG. Factor VNew Brunswick: Ala221-to-Val substitution results in reduced cofactor activity. Blood 1995; 86 (05) 1820-1827
• 44 Yang J, Mao H, Sun L. Congenital coagulation factor V deficiency with intracranial hemorrhage. J Clin Lab Anal 2022; 36 (11) e24705
• 45 Asselta R, Peyvandi F. Factor V deficiency. Semin Thromb Hemost 2009; 35 (04) 382-389
• 46 Rush B, Ellis H. The treatment of patients with factor-V deficiency. Thromb Diath Haemorrh 1965; 14 (1-2): 74-82
• 47 Thalji N, Camire RM. Parahemophilia: new insights into factor v deficiency. Semin Thromb Hemost 2013; 39 (06) 607-612
• 48 Bulato C, Novembrino C, Anzoletti MB. et al. “In vitro” correction of the severe factor V deficiency-related coagulopathy by a novel plasma-derived factor V concentrate. Haemophilia 2018; 24 (04) 648-656
• 49 Oeri J. Angeborener mangel an faktor V (parahaemophilie) verbunden mit echter haemophilie A bein zwei brudern. Mod Probl Paediatr 1954; 1: 575
• 50 Gobbi F. Heredity of combined deficiency of AHG and proaccelerin. Scand J Haematol 1966; 3 (03) 222-226
• 51 Girolami A, Violante N, Cella G, Patrassi G. Combined deficiency of factor V and factor VIII. A report of another case. Blut 1976; 32 (06) 415-422
• 52 Nichols WC, Seligsohn U, Zivelin A. et al. Linkage of combined factors V and VIII deficiency to chromosome 18q by homozygosity mapping. J Clin Invest 1997; 99 (04) 596-601
• 53 Nichols WC, Seligsohn U, Zivelin A. et al. Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII. Cell 1998; 93 (01) 61-70
• 54 Cunningham MA, Pipe SW, Zhang B, Hauri H-P, Ginsburg D, Kaufman RJ. LMAN1 is a molecular chaperone for the secretion of coagulation factor VIII. J Thromb Haemost 2003; 1 (11) 2360-2367
• 55 Zhang B, Cunningham MA, Nichols WC. et al. Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex. Nat Genet 2003; 34 (02) 220-225
• 56 Zheng C, Liu H, Ginsburg D, Zhang B. Critical role of calcium in the regulation of the ER-to-Golgi transport of FV and FVIII by the LMAN1-MCFD2 cargo receptor. Blood 2009; 114 (22) 2140
• 57 Shao Y, Wu W, Xu G, Wang X, Ding Q. Low factor V level ameliorates bleeding diathesis in patients with combined deficiency of factor V and factor VIII. Blood 2019; 134 (20) 1745-1754
• 58 Karimi M, Cairo A, Safarpour MM. et al. Genotype and phenotype report on patients with combined deficiency of factor V and factor VIII in Iran. Blood Coagul Fibrinolysis 2014; 25 (04) 360-363
• 59 Lin HY, Lin JS, Tsay W, Lin PT, Huang YC, Shen MC. A distinct common p.Gln317* mutation among causative LMAN1 genetic mutations of combined factor V and factor VIII deficiency in five Taiwanese families. Haemophilia 2022; 28 (01) e28-e31
• 60 Nichols WC, Terry VH, Wheatley MA. et al. ERGIC-53 gene structure and mutation analysis in 19 combined factors V and VIII deficiency families. Blood 1999; 93 (07) 2261-2266
• 61 Yamada T, Fujimori Y, Suzuki A. et al. A novel missense mutation causing abnormal LMAN1 in a Japanese patient with combined deficiency of factor V and factor VIII. Am J Hematol 2009; 84 (11) 738-742
• 62 Alsheikh S, Alghamdi R, Alqatari A, Alfareed A, AlSaleh M. Combined factor V and VIII deficiency with LMAN1 mutation: a report of 3 Saudi siblings. Am J Case Rep 2022; 23: e937312-e1
• 63 Fogarty H, Doyle MM, Campbell R. et al. Management of combined factor V and factor VIII deficiency in pregnancy. J Obstet Gynaecol 2019; 39 (02) 271-272
• 64 Spiliopoulos D, Kadir RA. Congenital factor V and VIII deficiency in women: a systematic review of literature and report of two new cases. Blood Coagul Fibrinolysis 2016; 27 (03) 237-241
• 65 Mathews N, Tasneem S, Hayward CPM. Rare inherited coagulation and fibrinolytic defects that challenge diagnostic laboratories. Int J Lab Hematol 2023; 45 (Suppl. 02) 30-43
• 66 Peyvandi F, Tuddenham EG, Akhtari AM, Lak M, Mannucci PM. Bleeding symptoms in 27 Iranian patients with the combined deficiency of factor V and factor VIII. Br J Haematol 1998; 100 (04) 773-776
• 67 Mansouritorgabeh H, Rezaieyazdi Z, Pourfathollah AA, Rezai J, Esamaili H. Haemorrhagic symptoms in patients with combined factors V and VIII deficiency in north-eastern Iran. Haemophilia 2004; 10 (03) 271-275
• 68 Viswabandya A, Baidya S, Nair SC. et al. Clinical manifestations of combined factor V and VIII deficiency: a series of 37 cases from a single center in India. Am J Hematol 2010; 85 (07) 538-539
• 69 Seligsohn U, Ramot B. Combined factor-V and factor-VIII deficiency: report of four cases. Br J Haematol 1969; 16 (05) 475-486
• 70 Shahverdi E, Abolghasemi H, Dolatimehr F, Beheshtian S, Melatshahi SC, Masoumi A. Combined factor V and factor VIII deficiency: a case report. Galen Med J 2016; 5 (01) 42-44
• 71 Kalas A, Hassan A, Alkhalifa O, Dali M, Shaheen F. A combined factor V and factor VIII deficiency: a case report. Cureus 2022; 14 (07) e26568
• 72 Brown L, Tilzer L, Plapp F. Factor V and VIII deficiency treated with therapeutic plasma exchange prior to redo mitral valve replacement. J Clin Apher 2017; 32 (03) 196-199
• 73 Devecioğlu O, Eryilmaz E, Celik D. et al. Circumcision in a combined factor V and factor VIII deficiency using desmopressin (DDAVP). Turk J Pediatr 2002; 44 (02) 146-147
• 74 Mladěnka P, Macáková K, Kujovská Krčmová L. et al; OEMONOM Researchers and Collaborators. Vitamin K - sources, physiological role, kinetics, deficiency, detection, therapeutic use, and toxicity. Nutr Rev 2022; 80 (04) 677-698
• 75 Stojanovski BM, Di Cera E. Comparative sequence analysis of vitamin K-dependent coagulation factors. J Thromb Haemost 2022; 20 (12) 2837-2849
• 76 Girolami A, Ferrari S, Cosi E, Santarossa C, Randi ML. Vitamin K-dependent coagulation factors that may be responsible for both bleeding and thrombosis (FII, FVII, and FIX). Clin Appl Thromb Hemost 2018; 24 (9 Suppl, Suppl): 42S-47S
• 77 Zhang B, Ginsburg D. Familial multiple coagulation factor deficiencies: new biologic insight from rare genetic bleeding disorders. J Thromb Haemost 2004; 2 (09) 1564-1572
• 78 Kuperman AA, Brenner B. Clinical perspective of congenital vitamin K-dependent coagulation factor deficiency. J Coagul Disord 2010; 2 (01) 1
• 79 Soute BA, Ulrich MM, Watson ADJ, Maddison JE, Ebberink RH, Vermeer C. Congenital deficiency of all vitamin K-dependent blood coagulation factors due to a defective vitamin K-dependent carboxylase in Devon Rex cats. Thromb Haemost 1992; 68 (05) 521-525
• 80 McMillan CW, Roberts HR. Congenital combined deficiency of coagulation factors II, VII, IX and X. Report of a case. N Engl J Med 1966; 274 (23) 1313-1315
• 81 Ayyash M, Chitlur M, Oldenburg J, Shaman M. Suspected vitamin K-dependent coagulation factor deficiency in pregnancy: a case report. Case Rep Womens Health 2022; 34: e00416
• 82 Brenner B, Sánchez-Vega B, Wu S-M, Lanir N, Stafford DW, Solera J. A missense mutation in γ-glutamyl carboxylase gene causes combined deficiency of all vitamin K-dependent blood coagulation factors. Blood 1998; 92 (12) 4554-4559
• 83 Spronk HM, Farah RA, Buchanan GR, Vermeer C, Soute BA. Novel mutation in the γ-glutamyl carboxylase gene resulting in congenital combined deficiency of all vitamin K-dependent blood coagulation factors. Blood 2000; 96 (10) 3650-3652
• 84 Hao Z, Jin D-Y, Chen X, Schurgers LJ, Stafford DW, Tie J-K. γ-Glutamyl carboxylase mutations differentially affect the biological function of vitamin K-dependent proteins. Blood 2021; 137 (04) 533-543
• 85 Al-Doory SA, Radaideh MA, Saleh SM, Al Sabbah MA. Congenital vitamin K-dependent clotting factors deficiency type 1: a rare bleeding disorder. Dubai Medical Journal. 2020; 3 (01) 8-12
• 86 Brenner B, Kuperman AA, Watzka M, Oldenburg J. Vitamin K-dependent coagulation factors deficiency. Semin Thromb Hemost 2009; 35 (04) 439-446
• 87 De Vries A, Alexander B, Goldstein R, Addelson E, Promisel E. A factor in serum which accelerates the conversion of prothrombin to thrombin; its determination and some physiologic and biochemical properties. Blood 1949; 4 (03) 247-258
• 88 Sayyadi M, Hassani S, Shams M, Dorgalaleh A. Status of major hemostatic components in the setting of COVID-19: the effect on endothelium, platelets, coagulation factors, fibrinolytic system, and complement. Ann Hematol 2023; 102 (06) 1307-1322
• 89 Sanders NL, Bajaj SP, Zivelin A, Rapaport SI. Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. Blood 1985; 66 (01) 204-212
• 90 Banner DW, D'Arcy A, Chène C. et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380 (6569): 41-46
• 91 Rosing J, Maurissen LF, Tchaikovski SN, Tans G, Hackeng TM. Protein S is a cofactor for tissue factor pathway inhibitor. Thromb Res 2008; 122 (Suppl. 01) S60-S63
• 92 Broze Jr GJ, Majerus PW. Purification and properties of human coagulation factor VII. J Biol Chem 1980; 255 (04) 1242-1247
• 93 Scarabin P-Y, Vissac A-M, Kirzin J-M. et al. Population correlates of coagulation factor VII. Importance of age, sex, and menopausal status as determinants of activated factor VII. Arterioscler Thromb Vasc Biol 1996; 16 (09) 1170-1176
• 94 Alexander B, Goldstein R, Landwehr G, Cook CD, Addelson E, Wilson C. Congenital SPCA deficiency: a hitherto unrecognized coagulation defect with hemorrhage rectified by serum and serum fractions. J Clin Invest 1951; 30 (06) 596-608
• 95 Duckert F, Koller F, Matter M. Purification and physiological properties of factor VII from plasma and serum; separation from prothrombin. Proc Soc Exp Biol Med 1953; 82 (02) 259-261
• 96 Nemerson Y. The reaction between bovine brain tissue factor and factors VII and X. Biochemistry 1966; 5 (02) 601-608
• 97 Nemerson Y, Esnouf MP. Activation of a proteolytic system by a membrane lipoprotein: mechanism of action of tissue factor. Proc Natl Acad Sci U S A 1973; 70 (02) 310-314
• 98 Bernardi F, Mariani G. Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis. Haematologica 2021; 106 (02) 351-362
• 99 Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci U S A 1977; 74 (12) 5260-5264
• 100 Hagen FS, Gray CL, O'Hara P. et al. Characterization of a cDNA coding for human factor VII. Proc Natl Acad Sci U S A 1986; 83 (08) 2412-2416
• 101 O'Hara PJ, Grant FJ, Haldeman BA. et al. Nucleotide sequence of the gene coding for human factor VII, a vitamin K-dependent protein participating in blood coagulation. Proc Natl Acad Sci U S A 1987; 84 (15) 5158-5162
• 102 Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb 1991; 11 (03) 540-546
• 103 O'Brien DP, Gale KM, Anderson JS. et al. Purification and characterization of factor VII 304-Gln: a variant molecule with reduced activity isolated from a clinically unaffected male. Blood 1991; 78 (01) 132-140
• 104 Bernardi F, Marchetti G, Pinotti M. et al. Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma. Arterioscler Thromb Vasc Biol 1996; 16 (01) 72-76
• 105 Marchetti G, Patracchini P, Papacchini M, Ferrati M, Bernardi F. A polymorphism in the 5′ region of coagulation factor VII gene (F7) caused by an inserted decanucleotide. Hum Genet 1993; 90 (05) 575-576
• 106 McVey JHBE, Boswell EJ, Takamiya O. et al. Exclusion of the first EGF domain of factor VII by a splice site mutation causes lethal factor VII deficiency. Blood 1998; 92 (03) 920-926
• 107 Herrmann FH, Wulff K, Auerswald G. et al; Greifswald Factor FVII Deficiency Study Group. Factor VII deficiency: clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene. Haemophilia 2009; 15 (01) 267-280
• 108 Lapecorella M, Mariani G. International Registry on Congenital Factor VII Deficiency. Factor VII deficiency: defining the clinical picture and optimizing therapeutic options. Haemophilia 2008; 14 (06) 1170-1175
• 109 Smith NL, Chen M-H, Dehghan A. et al; Wellcome Trust Case Control Consortium. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation 2010; 121 (12) 1382-1392
• 110 De Vries PS, Sabater-Lleal M, Huffman JE. et al; INVENT Consortium, MEGASTROKE Consortium of the International Stroke Genetics Consortium. A genome-wide association study identifies new loci for factor VII and implicates factor VII in ischemic stroke etiology. Blood 2019; 133 (09) 967-977
• 111 Qu C, Liu W, Chen L, Zhang L, Xue F, Yang R. Factor VII deficiency in China: Phenotype, genotype and current status of management. Br J Haematol 2023; 200 (03) 344-352
• 112 Akdeniz A, Ünüvar A, Ar MC. et al. Results of multicenter registry for patients with inherited factor VII deficiency in Turkey. Scand J Clin Lab Invest 2022; 82 (01) 28-36
• 113 Mariani G, Herrmann FH, Dolce A. et al; International Factor VII Deficiency Study Group. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost 2005; 93 (03) 481-487
• 114 Di Minno MND, Dolce A, Mariani G, Group SS. STER Study Group. Bleeding symptoms at disease presentation and prediction of ensuing bleeding in inherited FVII deficiency. Thromb Haemost 2013; 109 (06) 1051-1059
• 115 Napolitano M, Di Minno MND, Batorova A. et al. Women with congenital factor VII deficiency: clinical phenotype and treatment options from two international studies. Haemophilia 2016; 22 (05) 752-759
• 116 Abdul-Kadir R, Gomez K. Reproductive health and hemostatic issues in women and girls with congenital factor VII deficiency: a systematic review. J Thromb Haemost 2022; 20 (12) 2758-2772
• 117 van Royen EA, Lohman S, Voss M, Pondman KW. C-1 inactivator and cold-promoted activation of factor VII. J Lab Clin Med 1978; 92 (02) 152-163
• 118 Girolami A, Cattarozzi G, Dal Bo Zanon R, Toffanin F, Toffanin F. Factor VII Padua 2: another factor VII abnormality with defective ox brain thromboplastin activation and a complex hereditary pattern. Blood 1979; 54 (01) 46-53
• 119 Sevenet P-OKD, Kaczor DA, Depasse F. Factor VII deficiency: from basics to clinical laboratory diagnosis and patient management. Clin Appl Thromb Hemost 2017; 23 (07) 703-710
• 120 Mariani G, Mannucci PM, Mazzucconi MG, Capitanio A. Treatment of congenital factor VII deficiency with a new concentrate. Thromb Haemost 1978; 39 (03) 675-682
• 121 Hedner U, Glazer S, Pingel K. et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988; 2 (8621): 1193
• 122 Ramezanpour N, Zaker F, Biswas A, Dorgalaleh A. Inhibitor in congenital factor VII deficiency; a rare but serious therapeutic challenge—a systematic literature review. J Clin Med 2021; 10 (02) 211
• 123 Morawitz P. Beitrage zur kenntnis der blutgerinnung. Dtsch Arch Klin Med 1904; 79: 432-442
• 124 Telfer TP, Denson KW, Wright DR. A new coagulation defect. Br J Haematol 1956; 2 (03) 308-316
• 125 Hougie C, Barrow EM, Graham JB. Stuart clotting defect. I. Segregation of an hereditary hemorrhagic state from the heterogeneous group heretofore called stable factor (SPCA, proconvertin, factor VII) deficiency. J Clin Invest 1957; 36 (03) 485-496
• 126 Girolami A, Cosi E, Sambado L, Girolami B, Randi ML. Complex history of the discovery and characterization of congenital factor X deficiency. Semin Thromb Hemost 2015; 41 (04) 359-365
• 127 Girolami A, Cosi E, Sambado L, Girolami B, Randi ML. Complex history of the discovery and characterization of congenital factor X deficiency. Semin Thromb Hemost 2015; 41 (04) 359-365
• 128 Bachmann F. The discovery of factor X: a personal reminiscence. Thromb Haemost 2007; 98 (01) 16-19
• 129 Peyvandi F, Auerswald G, Austin SK. et al. Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency. Blood Rev 2021; 50: 100833
• 130 Leadley Jr RJ. Coagulation factor Xa inhibition: biological background and rationale. Curr Top Med Chem 2001; 1 (02) 151-159
• 131 Esmon CT. Targeting factor Xa and thrombin: impact on coagulation and beyond. Thromb Haemost 2014; 111 (04) 625-633
• 132 Scambler PJ, Williamson R. The structural gene for human coagulation factor X is located on chromosome 13q34. Cytogenet Cell Genet 1985; 39 (03) 231-233
• 133 Bernardi F, Marchetti G, Patracchini P. et al. Partial gene deletion in a family with factor X deficiency. Blood 1989; 73 (08) 2123-2127
• 134 Pfeiffer RA, Ott R, Gilgenkrantz S, Alexandre P. Deficiency of coagulation factors VII and X associated with deletion of a chromosome 13 (q34). Evidence from two cases with 46,XY,t(13;Y)(q11;q34). Hum Genet 1982; 62 (04) 358-360
• 135 de Grouchy J, Dautzenberg M-D, Turleau C, Beguin S, Chavin-Colin F. Regional mapping of clotting factors VII and X to 13q34. Expression of factor VII through chromosome 8. Hum Genet 1984; 66 (2-3): 230-233
• 136 Hertzberg M. Biochemistry of factor X. Blood Rev 1994; 8 (01) 56-62
• 137 Camire RM. Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics. J Thromb Thrombolysis 2021; 52 (02) 383-390
• 138 Brown DL, Kouides PA. Diagnosis and treatment of inherited factor X deficiency. Haemophilia 2008; 14 (06) 1176-1182
• 139 Bolton-Maggs PH, Wilde J, Pike GN. The Rarer Inherited Coagulation Disorders. Practical Hemostasis and Thrombosis. 2017:113–123
• 140 Peyvandi F, Garagiola I, Biguzzi E. Advances in the treatment of bleeding disorders. J Thromb Haemost 2016; 14 (11) 2095-2106
• 141 Peyvandi F, Menegatti M. Treatment of rare factor deficiencies in 2016. Hematology (Am Soc Hematol Educ Program) 2016; 2016 (01) 663-669
• 142 Ghadimi K, Levy JH, Welsby IJ. Prothrombin complex concentrates for bleeding in the perioperative setting. Anesth Analg 2016; 122 (05) 1287-1300
• 143 Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet 2007; 370 (9585): 439-448
• 144 Perry DJ. Factor X and Factor X deficiency. Textbook of Hemophilia. 2014:421–427
• 145 He R, Chen D, He S. Factor XI: hemostasis, thrombosis, and antithrombosis. Thromb Res 2012; 129 (05) 541-550
• 146 Seligsohn U. Factor XI deficiency in humans. J Thromb Haemost 2009; 7 (Suppl. 01) 84-87
• 147 Gailani D, Broze Jr GJ. Factor XI activation in a revised model of blood coagulation. Science 1991; 253 (5022): 909-912
• 148 Rosenthal RL, Dreskin OH, Rosenthal N. Plasma thromboplastin antecedent (PTA) deficiency; clinical, coagulation, therapeutic and hereditary aspects of a new hemophilia-like disease. Blood 1955; 10 (02) 120-131
• 149 Bolton-Maggs PH. Factor XI deficiency. Baillieres Clin Haematol 1996; 9 (02) 355-368
• 150 Bolton-Maggs PH. Factor XI deficiency – resolving the enigma?. Hematology (Am Soc Hematol Educ Program) 2009; 2009 (01) 97-105
• 151 Rosenthal RL, Dreskin OH, Rosenthal N. New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proc Soc Exp Biol Med 1953; 82 (01) 171-174
• 152 Wheeler AP, Gailani D. Why factor XI deficiency is a clinical concern. Expert Rev Hematol 2016; 9 (07) 629-637
• 153 Wright IS. The nomenclature of blood clotting factors. Thromb Diath Haemorrh 1962; 7 (02) 381-388
• 154 Leiba H, Ramot B, Many A. Heredity and coagulation studies in ten families with factor XI (plasma thromboplastin antecedent) deficiency. Br J Haematol 1965; 11 (06) 654-665
• 155 Rapaport SI, Proctor RR, Patch MJ, Yettra M. The mode of inheritance of PTA deficiency: evidence for the existence of major PTA deficiency and minor PTA deficiency. Blood 1961; 18 (02) 149-165
• 156 Handa S, Sterpi M, Sacchi De Camargo Correia G. et al. Obstetric and perioperative management of patients with factor XI deficiency: a retrospective observational study. Blood Adv 2023; 7 (10) 1967-1975
• 157 Zhang X, Lewandowska M, Aldridge M, Iglay K, Wolford E, Shapiro A. Global epidemiology of factor XI deficiency: a targeted review of the literature and foundation reports. Haemophilia 2023; 29 (02) 423-434
• 158 Asakai R, Chung DW, Ratnoff OD, Davie EW. Factor XI (plasma thromboplastin antecedent) deficiency in Ashkenazi Jews is a bleeding disorder that can result from three types of point mutations. Proc Natl Acad Sci U S A 1989; 86 (20) 7667-7671
• 159 Meijers JC, Davie EW, Chung DW. Expression of human blood coagulation factor XI: characterization of the defect in factor XI type III deficiency. Blood 1992; 79 (06) 1435-1440
• 160 Asakai R, Chung DW. The molecular genetics of factor XI deficiency. Baillieres Clin Haematol 1989; 2 (04) 787-799
• 161 Goldstein DB, Reich DE, Bradman N, Usher S, Seligsohn U, Peretz H. Age estimates of two common mutations causing factor XI deficiency: recent genetic drift is not necessary for elevated disease incidence among Ashkenazi Jews. Am J Hum Genet 1999; 64 (04) 1071-1075
• 162 Peretz H, Mulai A, Usher S. et al. The two common mutations causing factor XI deficiency in Jews stem from distinct founders: one of ancient Middle Eastern origin and another of more recent European origin. Blood 1997; 90 (07) 2654-2659
• 163 Gomez K, Bolton-Maggs P. Factor XI deficiency. Haemophilia 2008; 14 (06) 1183-1189
• 164 Lewandowska MD, Connors JM. Factor XI deficiency. Hematol Oncol Clin North Am 2021; 35 (06) 1157-1169
• 165 Bane CE, Neff AT, Gailani D. Factor XI Deficiency or Hemophilia C. Hemostasis and Thrombosis; 2014: 71-81
• 166 Kitchens CS. Factor XI: a review of its biochemistry and deficiency. Semin Thromb Hemost 1991; 17 (01) 55-72
• 167 Duga S, Salomon O. Congenital factor XI deficiency: an update. Semin Thromb Hemost 2013; 39 (06) 621-631
• 168 Bolton-Maggs PH, Perry DJ, Chalmers EA. et al. The rare coagulation disorders – review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10 (05) 593-628
• 169 Escobar MA. Less common congenital disorders of hemostasis. Consultative hemostasis and thrombosis: Elsevier; 2019: 59-79
• 170 Bolton-Maggs PH, Wensley RT, Kernoff PB. et al. Production and therapeutic use of a factor XI concentrate from plasma. Thromb Haemost 1992; 67 (03) 314-319
• 171 Collins PW, Goldman E, Lilley P, Pasi KJ, Lee CA. Clinical experience of factor XI deficiency: the role of fresh frozen plasma and factor XI concentrate. Haemophilia 1995; 1 (04) 227-231
• 172 Martín-Salces M, Jimenez-Yuste V, Alvarez MT, Quintana M, Hernández-Navarro F. Review: factor XI deficiency: review and management in pregnant women. Clin Appl Thromb Hemost 2010; 16 (02) 209-213
• 173 Biswas A, Ivaskevicius V, Seitz R, Thomas A, Oldenburg J. An update of the mutation profile of factor 13 A and B genes. Blood Rev 2011; 25 (05) 193-204
• 174 Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII deficiency. Semin Thromb Hemost 2009; 35 (04) 426-438
• 175 Barkan G, Gaspar A. Zur Frage der Reversibilität der Fibringerinnung. Biochem Z 1923; 136: 411
• 176 Robbins KC. A study on the conversion of fibrinogen to fibrin. American Journal of Physiology-Legacy Content. 1944; 142 (04) 581-588
• 177 Giangrande PL. Six characters in search of an author: the history of the nomenclature of coagulation factors. Br J Haematol 2003; 121 (05) 703-712
• 178 Laki K, Lóránd L. On the solubility of fibrin clots. Science 1948; 108 (2802): 280
• 179 Dorgalaleh A. The history of factor XIII deficiency. Semin Thromb Hemost 2024; 50 (01) 34-42
• 180 Duckert F. Documentation of the plasma factor XIII deficiency in man. Ann N Y Acad Sci 1972; 202: 190-199
• 181 Duckert F, Jung E, Shmerling DH. A hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. Thromb Diath Haemorrh 1960; 5 (02) 179-186
• 182 Muszbek L, Ariëns RA, Ichinose A. ISTH SSC Subcommittee on Factor XIII. Factor XIII: recommended terms and abbreviations. J Thromb Haemost 2007; 5 (01) 181-183
• 183 Board PG, Webb GC, McKee J, Ichinose A. Localization of the coagulation factor XIII A subunit gene (F13A) to chromosome bands 6p24—-p25. Cytogenet Cell Genet 1988; 48 (01) 25-27
• 184 Ichinose A, Davie EW. Characterization of the gene for the a subunit of human factor XIII (plasma transglutaminase), a blood coagulation factor. Proc Natl Acad Sci U S A 1988; 85 (16) 5829-5833
• 185 Ichinose A, McMullen BA, Fujikawa K, Davie EW. Amino acid sequence of the B subunit of human factor XIII, a protein composed of ten repetitive segments. Biochemistry 1986; 25 (16) 4633-4638
• 186 Ichinose A, Bottenus RE, Davie EW. Structure of transglutaminases. J Biol Chem 1990; 265 (23) 13411-13414
• 187 Board P, Coggan M, Miloszewski K. Identification of a point mutation in factor XIII A subunit deficiency. Blood 1992; 80 (04) 937-941
• 188 Kamura T, Okamura T, Murakawa M. et al. Deficiency of coagulation factor XIII A subunit caused by the dinucleotide deletion at the 5′ end of exon III. J Clin Invest 1992; 90 (02) 315-319
• 189 Standen GR, Bowen DJ. Factor XIII ABristol 1: detection of a nonsense mutation (Arg171–>stop codon) in factor XIII A subunit deficiency. Br J Haematol 1993; 85 (04) 769-772
• 190 Mikkola H, Syrjälä M, Rasi V. et al. Deficiency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. Blood 1994; 84 (02) 517-525
• 191 Hashiguchi T, Ichinose A. Molecular and cellular basis of deficiency of the b subunit for factor XIII secondary to a Cys430-Phe mutation in the seventh Sushi domain. J Clin Invest 1995; 95 (03) 1002-1008
• 192 Izumi T, Hashiguchi T, Castaman G. et al. Type I factor XIII deficiency is caused by a genetic defect of its b subunit: insertion of triplet AAC in exon III leads to premature termination in the second Sushi domain. Blood 1996; 87 (07) 2769-2774
• 193 Fisher S, Rikover M, Naor S. Factor 13 deficiency with severe hemorrhagic diathesis. Blood 1966; 28 (01) 34-39
• 194 Seitz R, Duckert F, Lopaciuk S, Muszbek L, Rodeghiero F, Seligsohn U. Study Group. ETRO Working Party on Factor XIII questionnaire on congenital factor XIII deficiency in Europe: status and perspectives. Semin Thromb Hemost 1996; 22 (05) 415-418
• 195 Lorand L, Urayama T, De Kiewiet JW, Nossel HL. Diagnostic and genetic studies on fibrin-stabilizing factor with a new assay based on amine incorporation. J Clin Invest 1969; 48 (06) 1054-1064
• 196 Wenzel E, Christ G. Untersuchungen über die Entstehung von Ammoniak im Zitratplasma nach Rekalzifizierung. Thromb Haemost 1969; 22 (06) 575-576
• 197 Hellstern P, Schilz K, von Blohn G, Wenzel E. Determination of factor XIII activity and of factor XIII inhibitors using an ammonium-sensitive electrode. Thromb Haemost 1983; 50 (02) 563-566
• 198 Muszbek L, Polgár J, Fésüs L. Kinetic determination of blood coagulation Factor XIII in plasma. Clin Chem 1985; 31 (01) 35-40
• 199 Kohler HP, Ichinose A, Seitz R, Ariens RA, Muszbek L. Factor XIII and Fibrinogen SSC Subcommittee of the ISTH. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011; 9 (07) 1404-1406
• 200 Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res 1999; 94 (05) 271-305
• 201 Egbring R, Andrassy K, Havemann K. et al. [Longtime therapy of congenital factor XIII deficiency using factor XIII concentrate]. Blut 1976; 33 (06) 367-376
• 202 Nugent D. Corifact™/Fibrogammin® P in the prophylactic treatment of hereditary factor XIII deficiency: results of a prospective, multicenter, open-label study. Thromb Res 2012; 130 (Suppl. 02) S12-S14
• 203 Lovejoy AE, Reynolds TC, Visich JE. et al. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood 2006; 108 (01) 57-62
• 204 Nascimento B, Goodnough LT, Levy JH. Cryoprecipitate therapy. Br J Anaesth 2014; 113 (06) 922-934
• 205 Golpayegani MV, Behnia H, Araghi MA, Ansari G. Factor XIII deficiency, review of the literature and report of a case. J Compr Pediatr 2016;7(04);
• 206 Watson JJ, Pati S, Schreiber MA. Plasma transfusion: history, current realities, and novel improvements. Shock: Injury, Inflammation, and Sepsis. Laboratory and Clinical Approaches. 2016; 46 (05) 468-479
• 207 O'Shaughnessy DF, Atterbury C, Bolton Maggs P. et al; British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126 (01) 11-28
• 208 Jones JH, Rizza CR, Hardisty RM, Dormandy KM, MacPherson JC. Combined deficiency of factor V and factor VIII (antihaemophilic globulin). A report of three cases. Br J Haematol 1962; 8 (02) 120-128
• 209 Olaiya O, Amos LE, Carpenter SL. Novel treatment of combined factor V and factor VIII deficiency with factor eight inhibitor bypass activity. Haemophilia 2020; 26 (01) e21-e22
• 210 Graham J, Hougie C. The Stuart factor and (hypoproconvertinemia?). The clotting defect and mode of inheritance. Proceedings of the International Society of Hematologists 1956:327